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 Royalties from UpToDate, Online
Environment is Contaminated
 Hospital environmental sites 
contaminated with
 VRE in areas housing VRE 
positive patients (7-29%)
 C. difficile in rooms housing 
patients with CDI (3-75%)
 Acinetobacter spp.  (3-50%)
 MRSA (20%)
Weber and Rutala. ICHE 2007;18:306-9. Weber et al. AJIC 2010;38:S25. 
Samore et al. Am J Med 1996; 100:32. Rutala et al. ICHE 2010. 
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Carling et al, SHEA 2010
Environment is Source of Transmission





MRSA OR=1.4 >7 days
VRE OR=1.4 >5 days
C. difficile HR=2.4 Months
Acinetobacter OR=4.2 >3 days
Huang SS et al. Arch Intern Med 2006; Nseir S Clin Microbiol Infect 2011; 















Improved Cleaning Decreases 
Contamination
 EVS education, observation
 Site cleaned 49%->85%
 Contamination monitored using 
cultures 
 Contamination decreased
 21% -> 8% (before cleaning)
 13% -> 8% (after cleaning)
Hota et al. J Hosp Infect 2009. Goodman et al. ICHE. 2008 Jul;29(7):593-9.  
Improved Cleaning Decreases Acquisition
 Quasi-experimental study in 10 
ICUs
 Enhanced cleaning intervention
 Feedback with UV-markers
 Pre-saturated cloths
 Education for EVS
 Acquisition determined by 
surveillance cultures on admission, 
weekly, and at discharge
 Rates of MDR acquisition dropped
 MRSA: 3.0% -> 1.5%
 VRE: 3.0% -> 2.2%
Datta et al. Arch Intern Med 2011;171:491. Hayden et al. CID 2006; 42: 1552; Mayfield et al. CID 2000. 





Cleaning compliance 48% 87% 85% 83%
HH compliance 40% 57% 29% 43%
Daily colonization pressure 0.49 0.36 0.26 0.18
Rate of VRE acquisition 33.5 16.9 12.1 10.4
 Use of bleach in BMT
 Decrease CDI from 8.6 ->3.3/1000 
pt-d
 Back to quats, rate back to 8.1/1000 
pt-d
HR=0.3
Improved Bleach Cleaning - RCT
 12-month, 16 hospital RCT – C. 
difficile
 Standard cleaning (bleach)
 Enhanced cleaning (education, bleach 
with fluorescent markers/feedback)
 Intervention led to
 Improved cleaning (increased 
fluorescent marker removal)
 Decreased recovery of C. difficile from 
environment
 But did not lead to reduction in CDI
10




UV Light - Overview
 UV light is bactericidal 
 UV light damages nucleic acid and destroys the ability of 
bacteria/viruses to replicate  
 Effective at reducing environmental bioburden in experimental 
conditions
 Competition – multiple companies now make UV-emitting devices





Rutala WA, Gergen MF, 






Knelson et al. ICHE 
2013;34:466.
UV Light – Reduced Infections?
 Multiple quasi-experimental studies 
published
 Example 
 3 heme-onc wards
 12 months
 Mixed effects Poisson regression 
model to compare intervention vs. 
baseline
 542/2,569 (21%) of rooms 
 IRR=0.49 [95% CI 0.26-0.94]; p=0.03
Pegues et al. ICHE 2017.
 Objective - to determine if enhanced methods for terminal room 
disinfection decrease acquisition and infection due to multidrug-
resistant organisms (MDROs)
 Design - prospective, multicenter, cluster-randomized, crossover 
trial to evaluate three strategies for enhanced terminal room 
disinfection
 Randomization at level of hospital
UV Light – BETR Disinfection
 28-month cluster RCT
 9 hospitals
 All hospitals used all 4 
cleaning strategies 
 Each strategy for 7 months
 Sequence randomized
 First month: “wash in” between 
phases













Anderson et al. Lancet 2017.
Definitions and Inclusion Criteria
Patient with 
colonization or 
infection due to 





















Docum nted infection or 







In room ≥ 24 hours
Exposure days = Time 
spent in “seed room”
Patient with 
colonization or 
infection due to 

















Same organism as the patient 
in the “seed room” AND
Positive culture while in room
OR
Potential “Incident Case”
Positive culture after stay in 
room
- 90 days (MRSA, VRE, MDRAB)
- 28 days (C. difficile)
Exclusion Criteria
 Incident cases were excluded if
 Had culture with same organism in prior 12 months OR
 Culture positive during first 48 hours of admission (“community-
onset”)
















n/exposure days 115/22,426 76/22,389 101/24,261 131/28,757
Cumulative rate 51.3 33.9 41.6 45.6
Average rate ±
STD






















n/exposure days 36/11,385 38/12,509
Cumulative rate 31.6 30.4
Average rate ± STD 33.0 ± 46.4 26.6 ± 19.2
RR (95% CI); p-value ref 1.0 (0.57-1.76); 1.0












n/exposure days 73/14,524 54/14,780 74/15,343 89/18,960
Cumulative rate 50.3 36.5 48.2 46.9
Average rate ±
STD


























n/exposure days 37/5,838 17/5,780 24/7,522 37/9,488
Cumulative rate 63.4 29.4 31.9 39.0
Average rate ±
STD



















UV vs. reference UV+Bleach vs. referenceBleach vs. reference
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Hospital-wide impact
 BETR D secondary analysis –
hospital-wide infections
 314,610 patients
 All target MDROs 
 11% decrease (RR 0.89 [95% CI 
0.79-1.00], p=0.052)
 Hospital-wide HA-CDI
 11% decrease (RR 0.89 [95% CI 
0.80-0.99], p=0.031)
 Hospital-wide VRE
 44% decrease (RR 0.56 [95% CI 
0.31-0.996], p=0.048)
Hospital-wide – Deeper Dive
 Why difference between patient-level and hospital-level C. difficile 
data?
 Bleach compliance? 
 Risk not related to individual room entry (ie, epi more complex)?  
 Ecological or indirect impact?
Hospital-wide – Deeper Dive (C. difficile)
Hospital-wide – Deeper Dive
 Why difference between patient-level and hospital-level C. difficile 
data? Multiple plausible explanations…
 MDRO travel together
 Target one MDRO, kill others
 Use of UV in other rooms
 Excluded patients (n=5,000)
 Place on contact precautions even if no MDRO
 Place on contact precautions for other organisms
 Place on contact precautions for syndromic surveillance
 Use of UV in targeted rooms may help subsequent patients
31
Summary – Patient Outcomes
UV Bleach Bleach+UV












Post-hoc – No 24 hr




 21,844 documented uses
 Cycle completed 97% of the time
 Range 90.8 – 98.8%
 Cycle type
 16,313 (75%) vegetative cycle
 3,651 (17%) spore cycle
 1,880 (9%) not documented 
TIME
 21,431 runs with documented 
times
 Median = 33 minutes (IQR 25-46)
 Variation by cycle
 Vegetative (med) = 30.4 (24-41)












Total time - N 78,413 127,028 114,101 102,227
Med [IQR] 79.4 [65.6-129.9] 88.9 [68.8-105.1] 82.6 [67.4-151] 87.5 [62.6-141.1]
Room cleaning - N 133,744 144,183 132,753 137,814





















Nerandzic et al. BMJ 
Infect Dis 2010, 10:197
Differences Between Machines?
 All can demonstrate 
reduction in bacteria
 Limited head-to-head data
 PX-UV vs. UV-C
 C. difficile, MRSA, and VRE on 
glass carriers
 10 minutes of irradiation at 4 
feet
 2 UV-C machines
 C. difficile and MRSA on steel 
carriers
Nerandzic et al. ICHE 2015;36:192. Cadnum et al. ICHE 2016;37:555.
Impact of Soilage?
 2 UV-C machines







 Low - 0.03% bovine serum 
albumin (BSA)
 Heavy – 10% BSA
 Faeces (synthetic)
Ali et al. J Hosp Infect 2017 epub ahead of print
UV Light – Reflective Paint?
Nanoscale inorganic oxides




*NOTE: Discussion largely related to vaporized hydrogen peroxide (VHP, 30-35% H2O2), not aerosolized hydrogen 
peroxide (aHP, 5-7% H2O2)
Hydrogen Peroxide – Overview 
 Heat generated vapor – 30-35% aqueous H2O2
 Fewer companies (currently)
 Highly effective
 EPA-registered “sterilants”










• PRE: 24% 
• POST:12%




Hydrogen Peroxide – Decreased Infections?
 5 wards with a high incidence of C. difficile 
 HPV was injected into sealed wards and individual patient rooms using 
generators until approx 1 micron film of HP was achieved on the surface
 11/43 (25.6%) surface samples yielded C. difficile compared to 0/27 (0%) after 
HPV decontamination
 The incidence of nosocomial CDI was significantly lower during the 
intervention period
 Conclusion: HPV was efficacious in eradicating C. difficile from contaminated 
surfaces






Boyce et al. ICHE 2008; 
29:723.
Prospective, Controlled Study
 30-month prospective cohort on 6 high risk units
 Controlled study –
 12 month baseline period
 3 control units
 3 intervention units – HPV used in rooms of patients known to have MDROs
 Patients in rooms treated with HPV had 64% decrease in 
acquisition of MDRO
 Most due to decrease in VRE






Passaretti et al. CID 2013
Feasibility
 Biggest issue is related to turn-
around time
 Originally quoted as up to 4-5 hours
 Hopkins trial = 1.5 to 3 hours
 1,565 rooms in 500-bed teaching 
hospital
 Mean occupancy of hospital = 94%
 HP system run by personnel from 
company 
 Total added time ~3.5 hours of 
additional turnover time
 ~3 hours from machine





 Experimental conditions in 15 
rooms
 C. difficile spores
 Biologic indicators (G. 
stearothermophilus)
 Log reduction greater for HP than 
UV
 >6 v ~2 (p<0.0001)
 More growth if “shadow”
 HP twice as much additional time




 Only use at terminal clean
 Increases turnover time 
 Evidence based





 Only use at terminal clean
 Increases time even more
 Evidence based 
 RCT data (single center)
 More logistical hurdles
 More effective (Cdiff)
Take Home Points
 Environmental disinfection is important
 Standard approaches are insufficient
 Enhanced disinfection is needed
 Novel strategies exist to improve environmental disinfection 
 UV and HP have emerged as the leading, evidence-based 
strategies 
 But have significant logistical hurdles to overcome
 Exciting times!
 Increasing amount of data to support the use of these enhanced strategies
dcasip.medicine.duke.edu
Questions?
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